IKZF1 and acute lymphoblastic leukemia: In ALL-BFM protocols, IKZF1 deletions acted as an independent risk factor, with the lower 5-year EFS than wild-type IKZF1 (0.69% vs. 0.85%, P < 0.0001) (51).